{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105000","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.172457+00:00","generated_at":"2026-05-17T18:12:23.528814+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioAtla Q2 net loss $18.7M; cash $18.2M; Oz-V 45% ORR in HPV+ OPSCC","bullets":["Net loss of $18.7M for Q2 2025 vs $21.1M in Q2 2024; R&D expense down to $13.7M.","Cash and cash equivalents $18.2M as of June 30, 2025, down from $49.0M at Dec 31, 2024.","BA3182 (EpCAM x CD3 TCE) Phase 1 dose-escalation ongoing; data readout expected 2H 2025.","Oz-V (CAB-ROR2-ADC) shows 45% ORR (5/11) in 2L+ HPV+ OPSCC; FDA meeting planned in 3Q 2025.","Company advancing partnering discussions; confident in closing at least one transaction in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105000","json":"https://secwatch.observer/filing/0000950170-25-105000.json","markdown":"https://secwatch.observer/filing/0000950170-25-105000.md","text":"https://secwatch.observer/filing/0000950170-25-105000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017025105000/0000950170-25-105000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017025105000/bcab-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:12:23.528814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}